Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

• Autores: Sparano, JA, Gray, RJ, Makower, DF, Pritchard, KI, Albain, KS, Hayes, DF, Geyer, CE Jr, Dees, EC, Perez, EA, Olson, JA Jr, Zujewski, J, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Paik, S, Wood, WC, Ravdin, P, Keane, MM, Gomez, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer, DL, Kaklamani, VG, Atkins, JN, Berenberg, JL, Sledge, GW
• Formato: artículo
• Fecha de Publicación: 2015
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/122
• Enlace del recurso: https://hdl.handle.net/20.500.14703/122
• Nivel de acceso: acceso abierto
• Materia: 21-Gene Expression Assay; Breast Cancer; https://purl.org/pe-repo/ocde/ford#3.02.21

Prior studies with the use of a prospective–retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker.